Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH SUMMARY

Towards personalized treatment of smoking-related lung cancers

An innovative approach to a phase II clinical trial aims to test the effects of multiple targeted treatments simultaneously in participants in the UK National Lung Matrix Trial. The design makes it possible to study small numbers of people with rare mutations in non-small-cell lung tumours.
  1. Gary Middleton

    1. Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

This is a summary of Middleton, G. et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature https://doi.org/10.1038/s41586-020-2481-8 (2020).

Access options

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-021-01113-9

References

  1. Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).

    Article  PubMed  Google Scholar 

  2. Blakely, C. M. et al. Nature Genet. 49, 1693–1704 (2017).

    Article  PubMed  Google Scholar 

  3. Castiglione, R. et al. Mod. Pathol. 32, 627–638 (2019).

    Article  PubMed  Google Scholar 

  4. McFadden, D. G. et al. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).

    Article  PubMed  Google Scholar 

  5. Yuan, G. et al. Nature 590, 504–508 (2021).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

G.M. reported receiving research funding from Bristol-Myers Squibb, Kael-Gemvax, Merck Sharp & Dome and Plexxikon, and personal fees from BioLineRx, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dome and Roche.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links